cytarabine has been researched along with Male Genital Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abruzzo, LV; Al-Quran, SZ; Lin, P; Medeiros, LJ; Olivares, A; Stephens, TW | 1 |
| Bagshawe, KD; Begent, RH; Brampton, M; Holden, L; Ledermann, JA; Newlands, ES; Rustin, GJ | 1 |
2 other study(ies) available for cytarabine and Male Genital Neoplasms
| Article | Year |
|---|---|
Myeloid sarcoma of the urinary bladder and epididymis as a primary manifestation of acute myeloid leukemia with inv(16).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Genital Neoplasms, Male; Humans; Idarubicin; In Situ Hybridization; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid; Urinary Bladder Neoplasms | 2006 |
The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dactinomycin; Etoposide; Genital Neoplasms, Male; Germinoma; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Time Factors; Vinblastine; Vincristine | 1994 |